Clinical Research Directory
Browse clinical research sites, groups, and studies.
Adjunctive Fosfomycin for Treatment of Staphylococcus Aureus Bacteraemia
Sponsor: Hospital Universitari de Bellvitge
Summary
Staphylococcus aureus bacteraemia is a frequent and life-threatening infection, despite current standard antibiotic monotherapy. This study aims to clarify the role of fosfomycin as an adjunctive therapy for improving outcomes in patients with this serious infection. Two clinical trials suggested that adjunctive fosfomycin therapy might offer a clinical benefit in certain cases, but the results are inconclusive. We aim to analyse pooled data from these trials in order to identify subgroups of patients that might benefit most from this therapy.
Official title: Adjunctive Fosfomycin for Treatment of Staphylococcus Aureus Bacteraemia: Protocol for a Pooled Post-hoc Analysis of Two Randomised Clinical Trials
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
369
Start Date
2024-11-01
Completion Date
2025-01-31
Last Updated
2024-11-22
Healthy Volunteers
No
Conditions
Locations (6)
The Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity
Melbourne, Victoria, Australia
Institute of Health Policy, Management and Evaluation, University of Toronto
Toronto, Ontario, Canada
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain
Germans Trias i Pujol Research Institute and Hospital (IGTP)
Badalona, Catalonia, Spain
Hospital Clinic de Barcelona
Barcelona, Catalonia, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Catalonia, Spain